News


All series


All News

Richard Finn, MD, professor of Medicine at the Geffen School of Medicine at the University of California Los Angeles, discusses both the recent advances and remaining unmet needs in hepatocellular carcinoma.

A supplemental new drug application has been submitted to the FDA seeking approval for the combination of copanlisib and rituximab for the treatment of relapsed indolent B-cell non-Hodgkin’s Lymphoma and is outside of the FDA accelerated approved indication for the treatment of relapsed follicular lymphoma who have received at least 2 prior systemic therapies.

The Association of Community Cancer Centers announced the launch of CANCER BUZZ TV, its video podcast channel aimed at informing oncology professionals of the latest developments in cancer care.

Type C meeting responses from the FDA have led to the finalization of the clinical development approach of STAR-OLZ, a multi-day transdermal olanzapine patch, for the treatment of chemotherapy induced nausea and vomiting.

Treatment with [vic-]trastuzumab duocarmazine (SYD985) demonstrated a statistically significant improvement in progression-free survival compared with physician’s choice of treatment in patients with pretreated HER2-positive unresectable locally advanced or metastatic breast cancer, meeting the primary end point of the phase 3 TULIP study, according to a press release from Byondis B.V.